Besifloxacin
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
The skill confirms this is a TxGNN pipeline task. The system prompt already provides the full report generation specification (v5). I’ll now generate the report directly from the Evidence Pack.
Besifloxacin: From Bacterial Conjunctivitis to Bronchitis
One-Sentence Summary
Besifloxacin (Besivance®) is a fourth-generation fluoroquinolone antibiotic, currently formulated exclusively as an ophthalmic suspension and clinically proven for bacterial conjunctivitis. The TxGNN model predicts it may be effective for Bronchitis with a prediction score of 99.84%, however there are currently 0 clinical trials and 0 publications directly supporting this direction — evidence rests entirely on model prediction alone (Level L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial conjunctivitis (ophthalmic use; inferred from clinical trial context — no Taiwan registration found) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| US Market Status | Not marketed (0 registrations in queried database) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known clinical use, Besifloxacin belongs to the fluoroquinolone class of antibiotics — a drug class that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, two enzymes essential for bacterial DNA replication and repair. Its broad-spectrum antibacterial activity has been demonstrated through multiple completed Phase 3 and Phase 4 clinical trials, covering major gram-positive pathogens such as Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, and gram-negative organisms such as Haemophilus influenzae.
Bacterial conjunctivitis and bronchitis share overlapping causative pathogens — particularly S. pneumoniae and H. influenzae. Other fluoroquinolones in the same class (levofloxacin, moxifloxacin) are guideline-recommended treatments for acute bacterial bronchitis and community-acquired pneumonia. The TxGNN model likely captured this class-level antibacterial activity profile and extrapolated it to bronchitis, which is mechanistically coherent at the drug-class level.
However, a critical practical barrier exists. Besifloxacin is available only as a 0.6% ophthalmic topical suspension, and a dedicated Phase 1 pharmacokinetic study (NCT00407589) confirmed that systemic plasma concentrations following topical ocular administration are negligibly low — far below any therapeutically relevant threshold for pulmonary or systemic infection. Besifloxacin currently has no oral, inhaled, or intravenous formulation. Without development of a new dosage form, this mechanistic potential cannot be translated into clinical use for bronchitis.
Clinical Trial Evidence
Currently no related clinical trials registered for Besifloxacin in bronchitis.
Literature Evidence
Currently no related literature available for Besifloxacin in bronchitis.
US Market Information
No registrations found in the queried regulatory database (0 licenses as of data cutoff 2026-05-01).
Data Note: Besivance® (besifloxacin ophthalmic suspension 0.6%) holds US FDA approval for bacterial conjunctivitis (NDA 022308, approved 2009, Bausch & Lomb). The zero-registration result reflects the scope of the queried Taiwan regulatory database (TFDA), where Besifloxacin has no approved product — not the absence of any global market authorization.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predicted indication (bronchitis) carries L5 evidence — no clinical trials or published literature exist to support it — and Besifloxacin’s ophthalmic-only formulation with confirmed negligible systemic absorption creates a pharmacokinetic barrier that cannot be overcome without a new dosage form. Pursuing this indication as-is offers no viable development path.
To proceed, the following is needed:
- Regulatory data: Retrieve US FDA NDA 022308 (Besivance®) full label to populate the safety warnings, contraindications, and approved indication fields
- MOA data: Query DrugBank API (DB06771) for complete mechanism of action, pharmacodynamics, and pharmacokinetic parameters
- Formulation strategy: Any non-ophthalmic repurposing (bronchitis, urinary, systemic) requires first developing an oral or systemic formulation — a significant investment with uncertain advantage over generic fluoroquinolones already on the market
- Alternative repurposing target: Consider prioritizing Otitis Externa (Rank 8) instead. The mechanistic rationale is substantially stronger — fluoroquinolone ear drops are an established FDA-approved class, Besifloxacin’s in vitro MIC against Pseudomonas aeruginosa and MRSA is superior to approved otic competitors, and conversion from ophthalmic suspension to otic suspension is a lower regulatory and formulation hurdle
- Evidence gap on rank 3: The Post-Bacterial Disorder (Rank 3) indication returned 6 clinical trials (all ophthalmic, L3 evidence). A focused mechanistic analysis of whether post-infectious ocular complications qualify as a distinct repurposing opportunity is warranted before broader claims are made
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.